Carbamazepine effect on nerandomilast pharmacokinetics in healthy males

Phase 1, open-label, single-arm trial of nerandomilast, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point at 30 days and Maximum measured concentration of the analyte in plasma at 30 days. Started Aug 2025; status: completed.